Synaptic Bio is developing a tetravalent bispecific antibody platform designed around the biology of the immune synapse, with lead asset SYB302 targeting PD-1 and IL-25 for cancer immunotherapy.
SYB302 combines checkpoint blockade with IL-25 neutralization in a single bispecific molecule designed to drive PD-1 clustering, immune synapse exclusion, internalization, and degradation.
The platform addresses key limitations of current checkpoint inhibitors, including insufficient responses in colder tumors and immune-related adverse events that lead to treatment discontinuation.
Preclinical MSS-CRC models demonstrated substantially greater checkpoint tumor control compared with anti-PD-1 controls.
IL-25 neutralization is designed to mitigate inflammatory signaling associated with immune-related adverse events.
Former CEO at NanoPass, medical device and vaccine entrepreneur with deep drug development, translational, and transactional expertise.
Chief of Rheumatology at Columbia University and pioneer in IL-25 and immune synapse biology.
Former executive leadership roles at Merck, Tibotec, and Seres Therapeutics.
Clinical, regulatory, and product development leadership across oncology, infectious disease, and immunotherapy programs.
Synaptic Bio is open to strategic partnerships, scientific collaborations, and investor discussions related to immune checkpoint and immune synapse therapeutics.